BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 37622286)

  • 1. Divergent pathways of liver fat accumulation, oxidation, and secretion in lipodystrophy versus obesity-associated NAFLD.
    Klein RJ; Viana Rodriguez GM; Rotman Y; Brown RJ
    Liver Int; 2023 Dec; 43(12):2692-2700. PubMed ID: 37622286
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lipoprotein Insulin Resistance Index Reflects Liver Fat Content in Patients With Nonalcoholic Fatty Liver Disease.
    Vittal A; Shapses M; Sharma B; Sharma D; Sun Q; Sampson M; Lee W; Ben Yakov G; Rotman Y
    Hepatol Commun; 2021 Apr; 5(4):589-597. PubMed ID: 33860117
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adipose Tissue Insulin Resistance Predicts the Severity of Liver Fibrosis in Patients With Type 2 Diabetes and NAFLD.
    Kalavalapalli S; Leiva EG; Lomonaco R; Chi X; Shrestha S; Dillard R; Budd J; Romero JP; Li C; Bril F; Samraj G; Pennington J; Townsend P; Orlando F; Shetty S; Mansour L; Silva-Sombra LR; Bedossa P; Malaty J; Barb D; Gurka MJ; Cusi K
    J Clin Endocrinol Metab; 2023 Apr; 108(5):1192-1201. PubMed ID: 36378995
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sex differences in the association between adipose insulin resistance and non-alcoholic fatty liver disease in Chinese adults.
    Wei Y; Liu J; Wang G; Wang Y
    Biol Sex Differ; 2023 Oct; 14(1):69. PubMed ID: 37814297
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Crosstalk between adipose tissue insulin resistance and liver macrophages in non-alcoholic fatty liver disease.
    Rosso C; Kazankov K; Younes R; Esmaili S; Marietti M; Sacco M; Carli F; Gaggini M; Salomone F; Møller HJ; Abate ML; Vilstrup H; Gastaldelli A; George J; Grønbæk H; Bugianesi E
    J Hepatol; 2019 Nov; 71(5):1012-1021. PubMed ID: 31301321
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adipose tissue dysfunction and visceral fat are associated with hepatic insulin resistance and severity of NASH even in lean individuals.
    Saponaro C; Sabatini S; Gaggini M; Carli F; Rosso C; Positano V; Armandi A; Caviglia GP; Faletti R; Bugianesi E; Gastaldelli A
    Liver Int; 2022 Nov; 42(11):2418-2427. PubMed ID: 35900229
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of adipose tissue insulin resistance on metabolic parameters and liver histology in obese patients with nonalcoholic fatty liver disease.
    Lomonaco R; Ortiz-Lopez C; Orsak B; Webb A; Hardies J; Darland C; Finch J; Gastaldelli A; Harrison S; Tio F; Cusi K
    Hepatology; 2012 May; 55(5):1389-97. PubMed ID: 22183689
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Free fatty acid processing diverges in human pathologic insulin resistance conditions.
    Sekizkardes H; Chung ST; Chacko S; Haymond MW; Startzell M; Walter M; Walter PJ; Lightbourne M; Brown RJ
    J Clin Invest; 2020 Jul; 130(7):3592-3602. PubMed ID: 32191645
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of liver fat and insulin resistance as determinants of plasma aminotransferase elevation in nonalcoholic fatty liver disease.
    Maximos M; Bril F; Portillo Sanchez P; Lomonaco R; Orsak B; Biernacki D; Suman A; Weber M; Cusi K
    Hepatology; 2015 Jan; 61(1):153-60. PubMed ID: 25145475
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatic Steatosis and Insulin Resistance, But Not Steatohepatitis, Promote Atherogenic Dyslipidemia in NAFLD.
    Bril F; Sninsky JJ; Baca AM; Superko HR; Portillo Sanchez P; Biernacki D; Maximos M; Lomonaco R; Orsak B; Suman A; Weber MH; McPhaul MJ; Cusi K
    J Clin Endocrinol Metab; 2016 Feb; 101(2):644-52. PubMed ID: 26672634
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk interaction of obesity, insulin resistance and hormone-sensitive lipase promoter polymorphisms (LIPE-60 C > G) in the development of fatty liver.
    Hsiao PJ; Chen ZC; Hung WW; Yang YH; Lee MY; Huang JF; Kuo KK
    BMC Med Genet; 2013 May; 14():54. PubMed ID: 23688034
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Determinants of hyperglucagonemia in pediatric non-alcoholic fatty liver disease.
    Maruszczak K; Radzikowski K; Schütz S; Mangge H; Bergsten P; Forslund A; Manell H; Pixner T; Ahlström H; Kullberg J; Mörwald K; Weghuber D
    Front Endocrinol (Lausanne); 2022; 13():1004128. PubMed ID: 36133310
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Relationship between Type 2 Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease Measured by Controlled Attenuation Parameter.
    Chon YE; Kim KJ; Jung KS; Kim SU; Park JY; Kim do Y; Ahn SH; Chon CY; Chung JB; Park KH; Bae JC; Han KH
    Yonsei Med J; 2016 Jul; 57(4):885-92. PubMed ID: 27189281
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phenotypical heterogeneity linked to adipose tissue dysfunction in patients with Type 2 diabetes.
    Barchetta I; Angelico F; Del Ben M; Di Martino M; Cimini FA; Bertoccini L; Polimeni L; Catalano C; Fraioli A; Del Vescovo R; Morini S; Baroni MG; Cavallo MG
    Clin Sci (Lond); 2016 Oct; 130(19):1753-62. PubMed ID: 27458255
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Non-alcoholic fatty liver disease is associated with insulin resistance and lipid accumulation product in women with polycystic ovary syndrome.
    Macut D; Tziomalos K; Božić-Antić I; Bjekić-Macut J; Katsikis I; Papadakis E; Andrić Z; Panidis D
    Hum Reprod; 2016 Jun; 31(6):1347-53. PubMed ID: 27076501
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum adipocyte fatty acid-binding protein levels: An indicator of non-alcoholic fatty liver disease in Chinese individuals.
    Xu Y; Ma X; Pan X; He X; Wang Y; Bao Y
    Liver Int; 2019 Mar; 39(3):568-574. PubMed ID: 30554468
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Insulin Resistance, but Not Obstructive Sleep Apnea Is Associated with Hepatic Steatosis in Chinese Patients with Severe Obesity.
    Zhu C; Tang S; Xiao J; Zhang Y; Sun L; Zhang J; Ding L; Liu M
    Obes Facts; 2023; 16(4):344-355. PubMed ID: 36854279
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Simple proxies of insulin resistance identify obese metabolic dysfunction-associated fatty liver disease subjects with advanced liver disease.
    Petralli G; Salvati A; Tricò D; Ricco G; Colombatto P; Brunetto MR; Solini A
    Diabetes Metab Res Rev; 2024 Feb; 40(2):e3736. PubMed ID: 37839068
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Methionine restriction prevents the progression of hepatic steatosis in leptin-deficient obese mice.
    Malloy VL; Perrone CE; Mattocks DA; Ables GP; Caliendo NS; Orentreich DS; Orentreich N
    Metabolism; 2013 Nov; 62(11):1651-61. PubMed ID: 23928105
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatic ceramides dissociate steatosis and insulin resistance in patients with non-alcoholic fatty liver disease.
    Luukkonen PK; Zhou Y; Sädevirta S; Leivonen M; Arola J; Orešič M; Hyötyläinen T; Yki-Järvinen H
    J Hepatol; 2016 May; 64(5):1167-1175. PubMed ID: 26780287
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.